Singapore biotherapeutics firm Hummingbird bags $125m in series C round

Hummingbird Bioscience, a Singapore-based company focused on antibody discovery, pharmacology, and clinical development, has raised US$125 million in its latest round of funding.

More funding details

• Lead investor: Novo Holdings
• Other investors: Frazier Healthcare Partners, Octagon Capital, EDBI, Amgen Ventures, Droia Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge Group, and Altrium Capital Management
• Returning investors: SK, Heritas Capital, and Mirae Asset Venture Capital
• Stage: Series C

More company updates

• Hummingbird will use the funds to advance the clinical development of its assets, including its antibody products for fighting tumors. It also plans to develop precision therapeutics, including a treatment for multiple myeloma.
• Kenneth Harrison, a partner at Novo Ventures, will join Hummingbird’s board of directors, along with Dan Estes, a general partner at Frazier Healthcare Partners, and SK vice president Kiel Kim.
• In May 2020, the company raised US$25 million in an extended series B funding round led by SK Holdings to accelerate the development of new candidates into clinical trials, as well as strengthen its scientific and research and development capabilities.

For more coverage about the company, head here. You can also click on the link below to view the company’s key details and funding history.